keyword
MENU ▼
Read by QxMD icon Read
search

mRcc

keyword
https://www.readbyqxmd.com/read/28314328/comparison-of-tyrosine-kinase-inhibitor-versus-mammalian-target-of-rapamycin-inhibitor-as-second-line-molecular-targeted-therapy-for-patients-with-poor-risk-metastatic-renal-cell-carcinoma
#1
Hideaki Miyake, Satoshi Imai, Keita Tamura, Takayuki Sugiyama, Hiroshi Furuse, Seiichiro Ozono, Masato Fujisawa
AIM: The objective of this study was to compare the efficacies of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORI) as second-line molecular-targeted therapy in patients with poor-risk metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS: This study included 89 consecutive patients with mRCC who were classified into a poor-risk group after the failure of first-line molecular-targeted agent and subsequently received second-line targeted therapy...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28301684/economic-evaluation-of-nivolumab-as-a-second-line-treatment-for-advanced-renal-cell-carcinoma-from-us-and-chinese-perspectives
#2
Xiao Min Wan, Liu Bao Peng, Jin An Ma, Yuan Jian Li
BACKGROUND: Nivolumab is a new standard of care for patients with metastatic renal cell carcinoma (mRCC) and provides an overall survival benefit of 5.40 months in comparison with everolimus. This study evaluated the cost-effectiveness of nivolumab for the second-line treatment of mRCC from the perspective of US payers and identified the range of drug costs for which the addition of nivolumab to standard therapy could be considered cost-effective from a Chinese perspective. METHODS: A partitioned survival model was constructed to estimate lifetime costs, life-years, and quality-adjusted life-years (QALYs)...
March 16, 2017: Cancer
https://www.readbyqxmd.com/read/28271073/primary-tumor-characteristics-are-important-prognostic-factors-for-sorafenib-treated-patients-with-metastatic-renal-cell-carcinoma-a-retrospective-multicenter-study
#3
MULTICENTER STUDY
Sung Han Kim, Sohee Kim, Byung-Ho Nam, Sang Eun Lee, Choung-Soo Kim, Ill Young Seo, Tae Nam Kim, Sung-Hoo Hong, Tae Gyun Kwon, Seong Il Seo, Kwan Joong Joo, Kanghyon Song, Cheol Kwak, Jinsoo Chung
We aimed to identify prognostic factors associated with progression-free survival (PFS) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with sorafenib. We investigated 177 patients, including 116 who received sorafenib as first-line therapy, using the Cox regression model. During a median follow-up period of 19.2 months, the PFS and OS were 6.4 and 32.6 months among all patients and 7.4 months and undetermined for first-line sorafenib-treated patients, respectively. Clinical T3-4 stage (hazard ratio [HR] 2...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28270887/a-three-variable-model-predicts-short-survival-in-patients-with-newly-diagnosed-metastatic-renal-cell-carcinoma
#4
Mohsan Ali Syed, Carsten Nieder
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) have variable survival outcomes. When discussing management approaches and providing information to patients and caregivers, it is important to have realistic perspectives, especially if the expected prognosis is very unfavorable. In the present study, factors predicting this endpoint were analyzed. METHODS: Data from 60 patients treated in routine clinical practice were evaluated. Unfavorable prognosis was defined as death within approximately 3 months from diagnosis of mRCC (maximum 3...
April 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28270065/may-adjuvant-therapy-play-a-role-for-the-management-of-renal-cell-carcinoma-a-review-of-literature-and-ongoing-trials
#5
Carlo Messina, Elisa Zanardi, Francesco Boccardo
BACKGROUND: Renal cell carcinoma (RCC) is responsible for 4% of all neoplasms in adults and 80% of all primary renal tumours. In the European Union, there are almost 84000 new cases and 35000 deaths each year due to RCC. In the last five decade patients with localised RCC will develop recurrence of disease after nephrectomy in about 50% of cases. Considering the number of novel targeted therapies approved in the last years for the treatment of mRCC, there has been great interest to assess the efficacy of the same agents in the adjuvant setting...
February 13, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28268170/cytoreductive-nephrectomy-renal-cell-carcinoma-patients-with-venous-tumor-thrombus
#6
E Jason Abel, Philippe E Spiess, Vitaly Margulis, Viraj A Master, Michael Mann, Kamran Zargar, Leonardo D Borregales, Wade J Sexton, Datta Patil, Surena F Matin, Christopher G Wood, Jose A Karam
PURPOSE: Careful selection is critical to identify metastatic renal cell carcinoma (mRCC) patients who are most likely to benefit from cytoreductive nephrectomy (CN). Surgery for mRCC patients with tumor thrombus is complex and may not benefit some patients with very poor overall survival (OS). The objective of this study was to evaluate whether preoperative variables or risk stratification systems could predict OS following CN. METHODS: Prognostic factors for overall OS following surgery were evaluated in mRCC patients with venous tumor thrombus at 5 institutions from 2000-2014...
March 4, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28254206/discontinuing-vegf-targeted-therapy-for-progression-versus-toxicity-affects-outcomes-of-second-line-therapies-in-metastatic-renal-cell%C3%A2-carcinoma
#7
Guillermo De Velasco, Wanling Xie, Frede Donskov, Laurence Albiges, Benoit Beuselinck, Sandy Srinivas, Neeraj Agarwal, Jae Lyun Lee, James Brugarolas, Lori A Wood, Sun-Young Rha, Christian Kollmannsberger, Scott North, Ravindran Kanesvaran, Brian I Rini, Reuben Broom, Haru Yamamoto, Marina D Kaymakcalan, Daniel Y C Heng, Toni K Choueiri
BACKGROUND: A significant subgroup of metastatic renal cell carcinoma (mRCC) patients discontinue vascular endothelial growth factor-targeted therapies (VEGF-TT) because of toxicity. Whether clinical outcomes differ in patients who receive second-line (2L) targeted therapy on the basis of reason for discontinuation of first-line (1L) therapy is unknown. PATIENTS AND METHODS: Patients from 15 International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) centers who started 2L targeted therapy were included and the reason for discontinuation of 1L therapy retrospectively collected...
January 12, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28246756/-first-line-therapy-in-advanced-renal-cell-carcinoma-a-randomized-open-label-phase%C3%A2-iii-study-evaluating-the-efficacy-and-safety-of-pembrolizumab-mk-3475-in-combination-with-axitinib-compared-to-sunitinib-monotherapy-as-first-line-treatment-for-locally-advanced
#8
https://www.readbyqxmd.com/read/28244475/efficacy-and-safety-of-sorafenib-in-advanced-renal-cell-cancer-and-validation-of-heng-criteria
#9
A Joshi, A Ramaswamy, V Noronha, V M Patil, A Chandrasekharan, A Goel, A Sahu, N Sable, A Agrawal, S Menon, K Prabhash
INTRODUCTION: Sorafenib is an established upfront treatment option for metastatic RCC (mRCC). There is no published literature regarding its performance in Indian Patients. We present an analysis of Sorafenib use in our institute and attempt to validate the Heng criteria as a prognostic score in these patients. MATERIALS AND METHODS: Patients who received Sorafenib as first line treatment for advanced RCC from June 2012 to December 2015 were prognosticated by Heng criteria and retrospectively analysed for baseline demographics, toxicity, response and outcomes...
July 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28237182/correlation-of-c-met-expression-and-outcome-in-patients-with-renal-cell-carcinoma-treated-with-sunitinib
#10
Katriina Johanna Peltola, Patrick Penttilä, Juhana Rautiola, Heikki Joensuu, Erkki Hänninen, Ari Ristimäki, Petri Bono
BACKGROUND: Treatment of patients with metastatic renal cell carcinoma (mRCC) has improved substantially since the introduction of targeted therapies, but no predictive biomarkers are available. The proto-oncogene c-Met is involved in tumor angiogenesis, development, and metastasis. The main objective was to evaluate c-Met expression in sunitinib-treated patients with mRCC, including patients with bone metastases. METHODS: c-Met expression was analyzed from 137 formalin-fixed paraffin-embedded tumor samples using a validated immunostaining protocol...
February 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28230776/effects-and-side-effects-of-using-sorafenib-and-sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#11
REVIEW
Caroline Randrup Hansen, Daniela Grimm, Johann Bauer, Markus Wehland, Nils E Magnusson
In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines as first-line and second-line therapy in mRCC. Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect. Studies have compared newer targeted drugs to sorafenib and sunitinib in terms of PFS, OS, quality of life and safety profiles...
February 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28224821/lenvatinib-for-use-in-combination-with-everolimus-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-following-one-prior-anti-angiogenic-therapy
#12
REVIEW
Aine O'Reilly, James Larkin
In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents have demonstrated efficacy in this setting. Here in we profile one such therapy, the combination of lenvatinib and everolimus, and discuss the expanded options for therapy available in this setting. Areas covered: In this review, we discuss current algorithms for treatment of mRCC in both the first-line and second-line setting...
March 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28220024/molecular-subtypes-improve-prognostic-value-of-international-metastatic-renal-cell-carcinoma-database-consortium-prognostic-model
#13
Guillermo de Velasco, Aedín C Culhane, André P Fay, A Ari Hakimi, Martin H Voss, Nizar M Tannir, Pheroze Tamboli, Leonard J Appleman, Joaquim Bellmunt, W Kimryn Rathmell, Laurence Albiges, James J Hsieh, Daniel Y C Heng, Sabina Signoretti, Toni K Choueiri
INTRODUCTION: Gene-expression signatures for prognosis have been reported in localized renal cell carcinoma (RCC). The aim of this study was to test the predictive power of two different signatures, ClearCode34, a 34-gene signature model [Eur Urol 2014;66:77-84], and an 8-gene signature model [Eur Urol 2015;67:17-20], in the setting of systemic therapy for metastatic disease. MATERIALS AND METHODS: Metastatic RCC (mRCC) patients from five institutions who were part of TCGA were identified and clinical data were retrieved...
February 20, 2017: Oncologist
https://www.readbyqxmd.com/read/28216279/outcomes-and-drug-costs-of-sunitinib-regimens-for-metastatic-renal-cell-carcinoma-a-provincial-population-based-study
#14
Aleksi Suo, Urooj Iqbal, June Lim, Chel Lee, Kathy Gesy, Nayyer Iqbal, Tahir Abbas
BACKGROUND: Conventional sunitinib dosing in metastatic renal cell carcinoma (mRCC) administers 50 mg daily on a 4 weeks on/2 weeks off (4/2) schedule. Not all patients tolerate this regimen and many undergo modifications to schedule, dose, or both. MATERIAL AND METHODS: All patients with mRCC treated with sunitinib by the Saskatchewan Cancer Agency between January 1, 2006, and January 1, 2013, were included. Regimens were categorized as standard intermittent dosing (SID), modified intermittent schedule (MIS), modified intermittent dosing (MID), combination of modified schedule and dosing (MSD), or continuous dosing (CD)...
February 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28216278/outcomes-of-patients-with-metastatic-renal-cell-carcinoma-and-bone-metastases-in-the-targeted-therapy-era
#15
Sarathi Kalra, Jonathan Verma, Bradley J Atkinson, Surena F Matin, Christopher G Wood, Jose A Karam, Sue-Hwa Lin, Robert L Satcher, Pheroze Tamboli, Kanishka Sircar, Priya Rao, Paul G Corn, Nizar M Tannir, Eric Jonasch
BACKGROUND: Bone metastases (BMs) occur commonly in patients with metastatic renal cell carcinoma (mRCC). Tyrosine kinase inhibitors (TKIs) have improved the outcomes for patients with mRCC. However, data on the outcomes of mRCC patients with BMs treated with TKIs are limited. We describe the outcomes of patients with BMs treated with TKI therapy and compare them with the outcomes from a pre-TKI group. PATIENTS AND METHODS: Using an institutional tumor registry, a retrospective review of patients with mRCC from 2002 to 2003 and 2006 to 2007 was performed...
January 18, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28216276/prediction-of-everolimus-toxicity-and-prognostic-value-of-skeletal-muscle-index-in-patients-with-metastatic-renal-cell-carcinoma
#16
Edouard Auclin, Camille Bourillon, Eleonora De Maio, Marie Agnes By, Sofiane Seddik, Laure Fournier, Marie Auvray, Antoine Dautruche, Yann-Alexandre Vano, Constance Thibault, Florence Joly, Laurent Brunereau, Carlos Gomez-Roca, Christine Chevreau, Reza Elaidi, Stéphane Oudard
BACKGROUND: The objective of the study was to assess the prognostic role of skeletal muscle index (SMI) in metastatic renal cell carcinoma (mRCC) patients treated with everolimus, and its effect of on everolimus-induced toxicity. PATIENTS AND METHODS: Consecutive mRCC patients treated with everolimus between February 2007 and November 2014 underwent computed tomography scans at a single center performed by the same radiologist. SMI was assessed before everolimus treatment using the L3 cross-sectional area...
February 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28213730/impact-of-baseline-visceral-fat-accumulation-on-prognosis-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-systemic-therapy
#17
Ryuichi Mizuno, Akira Miyajima, Taizo Hibi, Aya Masuda, Toshiaki Shinojima, Eiji Kikuchi, Masahiro Jinzaki, Mototsugu Oya
The aim of this study was to evaluate the clinical significance of visceral fat accumulation as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapies. A total of 114 patients were retrospectively reviewed. All patients received systemic therapy for mRCC at Keio University hospital in Japan. The intra-abdominal visceral fat area was determined by computed tomography at the umbilical level. The visceral fat accumulation was defined as ≥100 cm(2). The mean visceral fat area was 107...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28199818/cabozantinib-versus-sunitinib-as-initial-targeted-therapy-for-patients-with-metastatic-renal-cell-carcinoma-of-poor-or-intermediate-risk-the-alliance-a031203-cabosun-trial
#18
Toni K Choueiri, Susan Halabi, Ben L Sanford, Olwen Hahn, M Dror Michaelson, Meghara K Walsh, Darren R Feldman, Thomas Olencki, Joel Picus, Eric J Small, Shaker Dakhil, Daniel J George, Michael J Morris
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozantinib compared with sunitinib as first-line therapy in patients with mRCC. Patients and Methods Eligible patients had untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria...
February 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28196874/prospective-evaluation-of-sunitinib-induced-cardiotoxicity-in-patients-with-metastatic-renal-cell-carcinoma
#19
Vivek Narayan, Stephen M Keefe, Naomi Haas, Le Wang, Igor Puzanov, Mary E Putt, Anna Catino, James Fang, Neeraj Agarwal, David Hyman, Amanda M Smith, Brian S Finkelman, Hari K Narayan, Steven Ewer, Chantal ElAmm, Daniel J Lenihan, Bonnie Ky
PURPOSE: To prospectively evaluate cardiotoxicity risk with sunitinib in metastatic renal cell carcinoma (mRCC) routine clinical practice using comprehensive echocardiography and biomarker phenotyping. PATIENTS AND METHODS: In a multi-center prospective study of 90 mRCC patients, echocardiography and biomarkers of cardiovascular injury and stress were quantified at baseline, 3.5, 15, and 33 weeks following sunitinib initiation. These "on-drug" visits corresponded to cycles 1, 3, and 6, respectively...
February 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28188447/a-prospective-observational-study-on-the-evaluation-of-everolimus-related-adverse-events-in-metastatic-renal-cell-carcinoma-after-first-line-anti-vascular-endothelial-growth-factor-therapy-the-afinite-study-in-france
#20
Florence Joly, Jean-Christophe Eymard, Laurence Albiges, Thierry Nguyen, Aline Guillot, Frederic Rolland, Dominique Spaeth, Brigitte Laguerre, Thierry Lebret, Nadia Kelkouli, Khemaies Slimane, Alain Ravaud
PURPOSE: The objective of the study was to describe the occurrence of stomatitis and noninfectious lung disease in patients with metastatic renal cell carcinoma (mRCC) treated with second-line everolimus in a real-world setting. METHODS: This multicenter, prospective, observational study was conducted in France by physicians with experience of treatment of patients with mRCC. Patients aged ≥18 years who received everolimus after first-line antivascular endothelial growth factor (VEGF) therapy were included in the study...
February 10, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
77808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"